Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer.
Karim A. Touijer
No relevant relationships to disclose
Yingbei Chen
No relevant relationships to disclose
Brett Stewart Carver
No relevant relationships to disclose
Jonathan A. Coleman
No relevant relationships to disclose
Vincent Paul Laudone
No relevant relationships to disclose
Melanie Hullings
No relevant relationships to disclose
Samantha Spenser Ehrlich
No relevant relationships to disclose
Mia DeNunzio
No relevant relationships to disclose
Victor E. Reuter
No relevant relationships to disclose
James Andrew Eastham
No relevant relationships to disclose
Daniel Costin Danila
No relevant relationships to disclose
Susan F. Slovin
No relevant relationships to disclose
Michael J. Morris
No relevant relationships to disclose
Yu Chen
No relevant relationships to disclose
Peter T. Scardino
No relevant relationships to disclose
Howard I. Scher
No relevant relationships to disclose
Dana E. Rathkopf
No relevant relationships to disclose